Skip to main content
All lobbying filings

INFUSION PROVIDERS ALLIANCE

INFUSION PROVIDERS ALLIANCE filed a Q4 report for INFUSION PROVIDERS ALLIANCE on January 20, 2026.

Lobbying for INFUSION PROVIDERS ALLIANCE

All filings by INFUSION PROVIDERS ALLIANCE · Everything INFUSION PROVIDERS ALLIANCE has reported

 Filing · LD-2 quarterly report Q4 report
Reporting period
4th Quarter 2025
Oct 1 - Dec 31 · Posted Jan 20, 2026
Expenses
$110,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
District of Columbia

Official filing document

 Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 2

Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to virtual supervision of infusion drugs. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Issues related to the 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F).

Advocating for access to and reimbursement for biosimilars.

 Bills named in this filing 1
  • H.R. 4299
    Protecting Patient Access to Cancer and Complex Therapies Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem